scopolamine butylbromide ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
458 7182-53-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • buscopan
  • scopolamine butyl hydroxide
  • scopolamine butylbromide
  • hyoscine butylbromide
  • butylscopolamine
  • butylscopolammonium
  • butylscopolamine bromide
  • n-butylscopolammonium
  • n-butylscopolammonium bromide
Antimuscarinic quaternary ammonium derivative of scopolamine used to treat cramps in gastrointestinal, urinary, uterine, and biliary tracts, and to facilitate radiologic visualization of the gastrointestinal tract.
  • Molecular weight: 360.47
  • Formula: C21H30NO4
  • CLOGP: -1.09
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 59.06
  • ALOGS: -5.29
  • ROTB: 8

Drug dosage:

DoseUnitRoute
60 mg O
60 mg P
60 mg R

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 3.69 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 1 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1951 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Abdominal pain 110.77 17.36 146 6580 236082 50362316
Constipation 45.06 17.36 85 6641 185623 50412775
Aphonia 35.83 17.36 19 6707 8459 50589939
Diarrhoea 33.23 17.36 160 6566 588316 50010082
Infective exacerbation of chronic obstructive airways disease 32.34 17.36 10 6716 1098 50597300
Colitis ulcerative 30.53 17.36 22 6704 16832 50581566
Acarodermatitis 29.74 17.36 9 6717 919 50597479
Vomiting 28.69 17.36 129 6597 460629 50137769
Colitis 26.45 17.36 29 6697 38500 50559898
Chemical burns of eye 25.84 17.36 5 6721 74 50598324
Essential tremor 25.83 17.36 8 6718 883 50597515
Naevus haemorrhage 24.28 17.36 5 6721 103 50598295
Lymphoedema 23.96 17.36 15 6711 9107 50589291
Metastatic gastric cancer 23.63 17.36 5 6721 118 50598280
Hepatitis E 23.30 17.36 8 6718 1221 50597177
Adrenocortical insufficiency acute 22.04 17.36 8 6718 1436 50596962
Purulent discharge 22.03 17.36 11 6715 4321 50594077
Urinary tract infection 19.73 17.36 70 6656 223950 50374448
Pancreatitis haemorrhagic 19.15 17.36 5 6721 298 50598100
Oligohydramnios 19.11 17.36 11 6715 5739 50592659
Head discomfort 19.08 17.36 14 6712 11005 50587393
Pharyngeal swelling 18.63 17.36 10 6716 4556 50593842
Arthropod bite 18.60 17.36 11 6715 6034 50592364
Drug diversion 18.57 17.36 6 6720 759 50597639
Skin warm 18.29 17.36 10 6716 4725 50593673
Subcutaneous abscess 18.01 17.36 10 6716 4872 50593526
Malaise 17.95 17.36 90 6636 335442 50262956
Encephalopathy neonatal 17.80 17.36 3 6723 19 50598379
Bronchospasm 17.41 17.36 15 6711 14839 50583559

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Abdominal pain 41.41 20.60 61 3112 135296 29436058
Genitalia external ambiguous 38.90 20.60 8 3165 205 29571149
Pancreatic neoplasm 37.19 20.60 10 3163 831 29570523
Congenital bladder anomaly 36.92 20.60 8 3165 265 29571089
Foetal hypokinesia 34.33 20.60 8 3165 370 29570984
Neonatal respiratory depression 33.64 20.60 8 3165 404 29570950
Anomaly of external ear congenital 31.30 20.60 6 3167 106 29571248
Vomiting 30.60 20.60 69 3104 212191 29359163
External auditory canal atresia 28.33 20.60 6 3167 178 29571176
Tumour invasion 25.67 20.60 6 3167 281 29571073
Foetal exposure during pregnancy 23.13 20.60 23 3150 33844 29537510
Foetal exposure during delivery 20.64 20.60 4 3169 75 29571279

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Abdominal pain 127.44 15.74 189 9161 312186 64177196
Diarrhoea 49.46 15.74 221 9129 722483 63766899
Constipation 49.28 15.74 105 9245 229232 64260150
Vomiting 44.20 15.74 177 9173 550940 63938442
Aphonia 33.82 15.74 19 9331 8678 64480704
Malaise 30.67 15.74 126 9224 396121 64093261
Colitis 30.49 15.74 40 9310 58634 64430748
Pancreatic neoplasm 29.22 15.74 10 9340 1385 64487997
Acarodermatitis 26.46 15.74 9 9341 1223 64488159
Intestinal obstruction 25.80 15.74 29 9321 36257 64453125
Naevus haemorrhage 23.85 15.74 5 9345 103 64489279
Chemical burns of eye 23.80 15.74 5 9345 104 64489278
Infective exacerbation of chronic obstructive airways disease 23.79 15.74 10 9340 2428 64486954
Levator syndrome 23.30 15.74 4 9346 26 64489356
Metastatic gastric cancer 23.00 15.74 6 9344 326 64489056
Colitis ulcerative 22.84 15.74 22 9328 23006 64466376
Tumour invasion 22.61 15.74 6 9344 349 64489033
Lower respiratory tract infection 22.23 15.74 45 9305 94569 64394813
Essential tremor 22.07 15.74 8 9342 1311 64488071
Nephrolithiasis 21.49 15.74 29 9321 43654 64445728
Urinary tract infection 18.95 15.74 75 9275 231521 64257861
Purulent discharge 18.74 15.74 11 9339 5450 64483932
Pharyngeal swelling 18.56 15.74 11 9339 5548 64483834
Vulvovaginal swelling 18.37 15.74 5 9345 320 64489062
Administration site swelling 18.31 15.74 5 9345 324 64489058
Myocarditis 18.27 15.74 17 9333 17026 64472356
Nausea 17.45 15.74 182 9168 785618 63703764
Lymphoedema 17.08 15.74 13 9337 9892 64479490
Enterocolitis 16.93 15.74 14 9336 12004 64477378
Arthropod bite 16.64 15.74 11 9339 6710 64482672
Metastases to oesophagus 16.52 15.74 3 9347 28 64489354
Hepatitis alcoholic 16.44 15.74 5 9345 475 64488907
Skin infection 16.12 15.74 15 9335 15022 64474360
Intercepted product storage error 16.03 15.74 4 9346 182 64489200

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A03BB01 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
BELLADONNA AND DERIVATIVES, PLAIN
Belladonna alkaloids, semisynthetic, quaternary ammonium compounds
ATC A03DB04 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
ANTISPASMODICS IN COMBINATION WITH ANALGESICS
Belladonna and derivatives in combination with analgesics
MeSH PA D018678 Cholinergic Agents
MeSH PA D018680 Cholinergic Antagonists
MeSH PA D018727 Muscarinic Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D010276 Parasympatholytics
MeSH PA D018373 Peripheral Nervous System Agents
CHEBI has role CHEBI:48876 muscarinic antagonists
CHEBI has role CHEBI:53784 antispasmodics

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Gastric spasm indication 196754001




๐Ÿถ Veterinary Drug Use

SpeciesUseRelation
Horses Abdominal pain (colic) associated with spasmodic colic Indication
Horses Flatulent colic Indication
Horses Simple impactions Indication

๐Ÿถ Veterinary products

ProductApplicantIngredients
Buscopan Injectable Solution Boehringer lngelheim Animal Health USA Inc. 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.24 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Muscarinic acetylcholine receptor M1 GPCR WOMBAT-PK
Muscarinic acetylcholine receptor M2 GPCR WOMBAT-PK
Muscarinic acetylcholine receptor M3 GPCR WOMBAT-PK
Muscarinic acetylcholine receptor M4 GPCR WOMBAT-PK

External reference:

IDSource
149-64-4 SECONDARY_CAS_RN
1085787 RXNORM
C0006519 UMLSCUI
CHEBI:32123 CHEBI
CHEMBL1256901 ChEMBL_ID
6852391 PUBCHEM_CID
CHEMBL1618102 ChEMBL_ID
DB09300 DRUGBANK_ID
003459 NDDF
1156229000 SNOMEDCT_US
395739004 SNOMEDCT_US
D002086 MESH_DESCRIPTOR_UI
2Z3E1OF81V UNII

Pharmaceutical products:

None